The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

the FDA requested that manufacturers cease selling Zantac and any generic alternatives. Tens of thousands of cancer-stricken patients filed personal injury and product liability lawsuits against ...

British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in the United States alleging that its heartburn drug Zantac caused cancer.

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...

GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly lower after it agreed a $2.2 billion settlement over lawsuits in the US, which alleged the drugmaker’s now ...

While the Company repeatedly claimed that scientific research did not support a correlation between Zantac and cancer ... What Is The Lawsuit About? The complaint filed in this class action ...

GSK claims to investors that its decision to remove Zantac ... of cancer in patients." The Company admitted it could not "quantify or reliably estimate the liability" it would face from lawsuits ...

Smith announces that a class action lawsuit has been filed on behalf ... research did not support a correlation between Zantac and cancer, the Deutsche Bank report stated that the total liability ...